Merck MK-7339-012

Long Non Small Cell - Merck

Merck MK-7339-012

Objective

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator(s)
Thomas Lowe, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials